| Naslov: | Higher EpCAM-positive extracellular vesicle concentration in ascites is associated with shorter progression-free survival of patients with advanced high-grade serous carcinoma |
|---|
| Avtorji: | ID Herzog, Maruša (Avtor)
ID Verdenik, Ivan (Avtor)
ID Kobal, Borut (Avtor)
ID Černe, Katarina (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (1000,64 KB)
MD5: 4CDF066D5824E42A7963A728DA5547D6
 URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/1422-0067/25/12/6780
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKC LJ - Univerzitetni klinični center Ljubljana
|
|---|
| Povzetek: | Platinum-resistant high-grade serous carcinoma (HGSC) is an incurable disease, so biomarkers that could help with timely treatment adjustments and personalized approach are extensively being sought. Tumor-derived extracellular vesicles (EVs) that can be isolated from ascites and blood of HGSC patients are such promising biomarkers. Epithelial cell adhesion molecule (EpCAM) expression is upregulated in most epithelium-derived tumors; however, studies on prognostic value of EpCAM overexpression in ovarian carcinoma have shown contradictory results. The aim of our study was to evaluate the potential of total and EpCAM-positive EVs as prognostic and predictive biomarkers for advanced HGSC. Flow cytometry was used to determine the concentration of total and EpCAM-positive EVs in paired pretreatment ascites and plasma samples of 37 patients with advanced HGSC who underwent different first-line therapy. We found that higher EpCAM-positive EVs concentration in ascites is associated with shorter progression-free survival (PFS) regardless of treatment strategy. We also found a strong correlation of EpCAM-positive EVs concentration between ascites and plasma. Our findings indicate that EpCAM-positive EVs in ascites of patients with advanced HGSC have the potential to serve as prognostic biomarkers for predicting early recurrence and thereby likelihood of more aggressive tumor biology and development of chemoresistance. |
|---|
| Ključne besede: | EpCAM, HGSC (ovarian cancer), biomarkers, extracellular vesicles, personalized medicine, prognosis |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Leto izida: | 2024 |
|---|
| Št. strani: | str. 1-15 |
|---|
| Številčenje: | Vol. 25, iss. 12, [article no.] 6780 |
|---|
| PID: | 20.500.12556/DiRROS-29964  |
|---|
| UDK: | 616-006 |
|---|
| ISSN pri članku: | 1422-0067 |
|---|
| DOI: | 10.3390/ijms25126780 |
|---|
| COBISS.SI-ID: | 209381635 |
|---|
| Opomba: |
Nasl. z nasl. zaslona;
Opis vira z dne 30. 9. 2024;
|
|---|
| Datum objave v DiRROS: | 10.06.2026 |
|---|
| Število ogledov: | 76 |
|---|
| Število prenosov: | 58 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
